Logo

Clinical Data Closes $56M Genaissance Acquisition

Oct 07, 2005

NEW YORK, Oct. 7 (GenomeWeb News) - Clinical Data has closed its acquisition of Genaissance Pharmaceuticals, following approval by the companies' stockholders, Clinical said today.

 

Effective immediately, Genaissance will no longer trade on Nasdaq under the ticker symbol GNSC. Clinical Data's Nasdaq ticker symbol is CLDA. 

 

Clinical Data announced the $56 million all-stock acquisition in June. Genaissance will continue to market its DNA and pharmacogenomics services, the company said.

 

Clinical Data is still in the process of acquiring biomarker discovery firm Icoria, "which will add additional capabilities in the area of molecular diagnostics," according to a company statement today.

Breaking News
The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.